JP2012505901A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505901A5
JP2012505901A5 JP2011532205A JP2011532205A JP2012505901A5 JP 2012505901 A5 JP2012505901 A5 JP 2012505901A5 JP 2011532205 A JP2011532205 A JP 2011532205A JP 2011532205 A JP2011532205 A JP 2011532205A JP 2012505901 A5 JP2012505901 A5 JP 2012505901A5
Authority
JP
Japan
Prior art keywords
wsp
fviii
antibody
item
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505901A (ja
JP4966434B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060633 external-priority patent/WO2010045321A2/en
Publication of JP2012505901A publication Critical patent/JP2012505901A/ja
Publication of JP2012505901A5 publication Critical patent/JP2012505901A5/ja
Application granted granted Critical
Publication of JP4966434B2 publication Critical patent/JP4966434B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532205A 2008-10-15 2009-10-14 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化 Expired - Fee Related JP4966434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10554808P 2008-10-15 2008-10-15
US61/105,548 2008-10-15
PCT/US2009/060633 WO2010045321A2 (en) 2008-10-15 2009-10-14 Pegylation of recombinant blood coagulation factors in the presence of bound antibodies

Publications (3)

Publication Number Publication Date
JP2012505901A JP2012505901A (ja) 2012-03-08
JP2012505901A5 true JP2012505901A5 (enExample) 2012-04-19
JP4966434B2 JP4966434B2 (ja) 2012-07-04

Family

ID=42035746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532205A Expired - Fee Related JP4966434B2 (ja) 2008-10-15 2009-10-14 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化

Country Status (9)

Country Link
US (1) US8143347B2 (enExample)
EP (1) EP2349341B1 (enExample)
JP (1) JP4966434B2 (enExample)
AU (1) AU2009303368B2 (enExample)
CA (1) CA2738064C (enExample)
DK (1) DK2349341T3 (enExample)
ES (1) ES2441941T3 (enExample)
PL (1) PL2349341T3 (enExample)
WO (1) WO2010045321A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
CN105237762B (zh) * 2015-10-27 2017-11-14 深圳市健元医药科技有限公司 Peg化亮丙瑞林
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
US12304928B2 (en) 2018-05-18 2025-05-20 Cz Biohub Sf, Llc Epitope restriction for antibody selection
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN111378026A (zh) * 2018-12-27 2020-07-07 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686112A (en) * 1983-01-13 1987-08-11 Rca Corporation Deposition of silicon dioxide
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6531298B2 (en) * 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US7074878B1 (en) * 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1446438A2 (en) * 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
EP1654290B1 (en) * 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
EP3184551A1 (en) * 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII

Similar Documents

Publication Publication Date Title
JP2012505901A5 (enExample)
Li et al. Lysine-PEG-modified polyurethane as a fibrinolytic surface: effect of PEG chain length on protein interactions, platelet interactions and clot lysis
JP2018035192A5 (enExample)
Goosen et al. Properties of a heparin‐poly (vinyl alcohol) hydrogel coating
EP2718724B1 (en) Diagnostic devices, methods and systems for detecting platelet factor 4 (pf4)/heparin antibodies
US6884628B2 (en) Multifunctional polymeric surface coatings in analytic and sensor devices
Nguyen et al. Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds
AU2003284304B2 (en) Surface coating comprising bioactive compound
JP2015506764A (ja) 止血創傷被覆材
AU2012262428C1 (en) Therapeutic proteins with increased half-life and methods of preparing same
AR084576A1 (es) Materiales y metodos para conjugar un derivado de acido graso hidrosoluble a una proteina
JPH02131769A (ja) 医療素子の基板および医療素子の製造方法
US12208132B2 (en) Therapeutic APAC molecule comprising heparin conjugated to a plasma protein
Jokiranta et al. Complement C3b interactions studied with surface plasmon resonance technique
RU2016121611A (ru) Конъюгаты белков свертывания крови
Moen et al. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems
JP2008530208A (ja) 万能前凝固薬
JP7676032B2 (ja) Ｐｅｇ－脂質
WO2018062263A1 (ja) 核酸の分析方法
Yavari et al. Anticoagulant therapy during cardiopulmonary bypass
Jung et al. QCM and AFM analysis of anticoagulant activities of sulfonated polymers against fibrin formation
Kuddushi et al. Evaluating Electrospun Polycaprolactone Fibers for Blood‐Contacting Applications
EP1174498A3 (en) Blood coagulation factor IX-activating protein and antibody thereto
JP2004510162A5 (enExample)
JPH02503033A (ja) インビトロ診断法およびそのために有用な手段